SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

USFDA completes inspection at Laurus Labs’ Visakhapatnam facility

09 Nov 2019 Evaluate

US Food and Drug Administration (USFDA) has completed inspection at Laurus Labs’ FDF & API Integrated Facility, Unit 2, at Visakhapatnam. The inspection was carried out from November 04 - 08, 2019.

The company has been issued with two observations which are procedural in nature. This is a product pre-approval audit by USFDA.

Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.

Laurus Labs Share Price

1177.10 10.60 (0.91%)
05-May-2026 09:09 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1824.10
Dr. Reddys Lab 1286.90
Cipla 1337.95
Zydus Lifesciences 901.10
Lupin 2348.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×